Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study

• Published in: Rheumatology and therapy. Vol. 11; no. 2; pp. 443 - 455
• Main Authors: Chandran, Vinod, Bessette, Louis, Thorne, Carter, Sheriff, Maqbool, Rahman, Proton, Gladman, Dafna D., Anwar, Sabeen, Jelley, Jennifer, Gaudreau, Anne-Julie, Chohan, Manprit, Sampalis, John S.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.04.2024; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Apremilast; Clinical outcomes; Family Medicine; General Practice; Inhibitor drugs; Internal Medicine; Medicine; Medicine & Public Health; NCT; NCT03608657; Original Research; Orthopedics; Patient satisfaction; Psoriatic arthritis; Quality of Life Research; Rheumatology; Side effects; Apremilast; Rheumatology; Psoriatic arthritis
• ISSN: 2198-6576; 2198-6584
• DOI: 10.1007/s40744-024-00641-w

Introduction The APPRAISE study was conducted to better understand the 12-month effectiveness, tolerability, and patient satisfaction with apremilast treatment for patients with psoriatic arthritis (PsA) in real-world settings. Methods APPRAISE (NCT03608657), a prospective, multicenter, observational study, enrolled adults with active PsA prescribed apremilast per routine care between July 2018 and March 2020. Patients were followed for 12 months with visits suggested every 4 months. The primary outcome measure was achievement of remission (REM) or low disease activity (LDA), defined as a Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) score ≤ 13. Results Of the 102 patients who enrolled, 45 (44.1%) discontinued the study by 12 months. Most patients (75.5%) had moderate or high disease activity, and 24.5% were in REM/LDA at baseline based on cDAPSA score. Achievement of cDAPSA REM/LDA was 63.7%, 67.2%, and 53.8% at months 4, 8, and 12, respectively. In those continuing in the study, significant improvements were seen in swollen and tender joint counts, pain visual analog scale, psoriasis body surface area, and complete dactylitis resolution. Enthesitis reduction was also observed. Improvements in treatment satisfaction and patient-reported outcomes, including Health Assessment Questionnaire-Disability Index and the 36-item Short Form physical and mental component scores, were observed over 12 months. The proportion of patients achieving a Patient-Acceptable Symptom State (PASS) increased significantly from baseline at months 4, 8, and 12 ( P  < 0.001). Apremilast was well tolerated; the most frequent adverse events (AEs) leading to discontinuation were diarrhea (9/102 [8.8%]), nausea (4/102 [3.9%]), and migraine (4/102 [3.9%]). Conclusion In this real-world study conducted in Canadian rheumatology clinics, apremilast demonstrated clinical effectiveness in patients with active PsA, along with patient satisfaction with treatment. Safety findings were consistent with previously reported clinical data. Trial Registration ClinicalTrials.gov identifier, NCT03608657.